Skip to main content
Clinical Trials/IRCT20220116053732N1
IRCT20220116053732N1CompletedPhase 3

Evaluation of protective effect of Royal Jelly on Serum Oxidative Stress markers and Interleukin-1Beta of Patients with Multiple Sclerosis.

Dezfoul University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20 years to 45 years (—)
Sex
All

Inclusion Criteria

  • Age of patients should be 20-45
  • The sub type of M.S should be Relapsing-Remitting MS (RRMS).
  • The diagnosis of RRMS is confirmed by a neurologist based on neurological examination and imaging.
  • Patients should be treated with Interferon for at least 6 months.

Exclusion Criteria

  • Patients with anemia, Chronic Heart Disease, lung disease, Diabetic mellitus, Autoimmune diseases such as Rheumatoid Arthritis, SLE, ...
  • Patients treated with corticosteroids or ACTH.
  • Use of any supplements by patients.
  • History of asthma and allergies in the patient.
  • Occurrence of allergic symptoms during the study
  • Occurrence of a MS attack during the study period.
  • The patient' s refuse to continue study.

Investigators

Sponsor
Dezfoul University of Medical Sciences

Similar Trials